Thrivent Financial for Lutherans Sells 1,000,775 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Thrivent Financial for Lutherans trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 45.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,186,671 shares of the biopharmaceutical company's stock after selling 1,000,775 shares during the quarter. Thrivent Financial for Lutherans owned about 0.10% of Gilead Sciences worth $109,650,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. FMR LLC grew its position in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $207,340,000. Finally, Point72 Asset Management L.P. grew its position in shares of Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock valued at $193,274,000 after purchasing an additional 1,793,145 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Gilead Sciences Trading Up 1.1 %

Shares of NASDAQ GILD traded up $1.21 during midday trading on Friday, reaching $107.08. 26,496,292 shares of the stock were exchanged, compared to its average volume of 6,797,069. The business has a 50-day simple moving average of $103.68 and a two-hundred day simple moving average of $93.75. The company has a market capitalization of $133.35 billion, a price-to-earnings ratio of 289.41, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Bank of America increased their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Morgan Stanley raised their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 11th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.